Ayahuasca Improves Self-perception of Speech Performance in Subjects With Social Anxiety Disorder
Rafael G. Dos Santos, Flávia de Lima Osório, Juliana Mendes Rocha, Giordano Novak Rossi, José Carlos Bouso, Lucas S. Rodrigues, Gabriela de Oliveira Silveira, Maurı́cio Yonamine, Jaime E. C. Hallak
Journal of Clinical Psychopharmacology June 23, 2021 DOI: 10.1097/jcp.0000000000001428 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Sample size | 17 |
| Population | Volunteers with social anxiety disorder |
| Intervention | Ayahuasca |
| Duration | 21-day follow-up |
| Topics | Anxiety Ayahuasca |
| Keywords | Social anxiety Perception Audiology Clinical psychology Cognitive psychology Psychotherapist |
| Citations | 85 |
| Key findings | Ayahuasca significantly improved self-perception of speech performance in socially anxious individuals, independent of task-related anxiety and emotion recognition. |
Abstract
Abstract Background Ayahuasca is a classic hallucinogen with anxiolytic and antidepressive properties. Anecdotal evidence also suggests that it improves performance (eg, singing, speech). This controlled trial assessed the effects of ayahuasca on speech performance and anxiety in individuals with social anxiety disorder.
Methods: Seventeen volunteers with social anxiety disorder participated in a pilot, proof-of-concept, randomized, parallel-group trial. Self-perception of performance during a public-speaking test was assessed with the Self-statements During Public Speaking Scale primary outcome). Secondary outcomes included anxiety/subjective effects (Visual Analog Mood Scale; Bodily Symptoms Scale), recognition of emotions in facial expressions (REFE), tolerability measures (cardiovascular measures, self-reports), and brain-derived neurotrophic factor plasma levels. Effects on anxiety and REFE were assessed again 7, 14, and 21 days postdrug.
Findings: Compared with placebo, ayahuasca significantly improved self-perception of speech performance (Self-statements During Public Speaking Scale) and increased somatic symptoms (Bodily Symptoms Scale). There was also a significant time × group interaction in the cognitive deterioration Visual Analog Mood Scale factor and a significant effect of time in the REFE task, especially in reaction time. Other measures were not significantly modified. Ayahuasca was well tolerated, producing mainly nausea, gastrointestinal discomfort, and vomiting.
Conclusions: Ayahuasca improved self-perception of speech performance in socially anxious individuals. These effects occurred independent of task-related anxiety and REFE, suggesting that ayahuasca could specifically improve the cognitive aspect of speech performance. Further studies should try to unveil the mechanisms involved in the effects of ayahuasca and to better understand its effects on anxiety.
In the evidence
This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.
-
Ayahuasca significantly improved self-perception of speech performance compared with placebo, but other anxiety and emotion-recognition measures were not significantly modified.
Synthesized
Comparable studies
Other randomized controlled trials on ayahuasca for anxiety, most cited first.
Citations in the library
Cited by 75
- Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review Journal of Psychopharmacology August 26, 2022
- Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis. Psychiatry Research May 1, 2024
- Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders Molecules April 13, 2022
- The psychedelic afterglow phenomenon: a systematic review of subacute effects of classic serotonergic psychedelics Therapeutic Advances in Psychopharmacology 2023
- Safety and risk assessment of psychedelic psychotherapy: A meta-analysis and systematic review. Psychiatry Research May 1, 2024
and 70 more in the library
Cites 29
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
and 24 more in the library